Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0WMIEE
ADC Name
37235999 ADC 401-4
Synonyms
ADC 401-4
   Click to Show/Hide
Organization
Shanghai Institute for Advanced Immunochemical Studies ShanghaiTech University.
Drug Status
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
B7-H3 mAb 401
  Antibody Info 
Antigen Name
CD276 antigen (CD276)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Fmoc-Val-Cit-PAB-PNP
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
13.18
nM
CVCL_0022
Glioblastoma
Half Maximal inhibitory Concentration (lC50) 
35.48
nM
CVCL_0021
Astrocytoma
Half Maximal inhibitory Concentration (lC50) 
239.88
nM
CVCL_0022
Glioblastoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 13.18 nM High B7-H3 expression (B7-H3 +++)
Method Description
Cancer cell lines U87, U251, U87/B7-H3 KO cells (3000 cells per well) at logarithmic growth stage were seeded in 96-well plates and allowed to adhere overnight at 37 °C in a humidified incubator of 5% CO2. After that, ADCs, 401 and MMAE were diluted at a certain concentration gradient and added to cell plates in triplicate, the cells were treated at 37 °C with 5% CO2 for 72 h. In addition, the complete medium without cells served as the blank and the cells cultured in medium alone served as vehicle control.

   Click to Show/Hide
In Vitro Model Glioblastoma U87 cells CVCL_0022
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 35.48 nM High B7-H3 expression (B7-H3 +++)
Method Description
Cancer cell lines U87, U251, U87/B7-H3 KO cells (3000 cells per well) at logarithmic growth stage were seeded in 96-well plates and allowed to adhere overnight at 37 °C in a humidified incubator of 5% CO2. After that, ADCs, 401 and MMAE were diluted at a certain concentration gradient and added to cell plates in triplicate, the cells were treated at 37 °C with 5% CO2 for 72 h. In addition, the complete medium without cells served as the blank and the cells cultured in medium alone served as vehicle control.

   Click to Show/Hide
In Vitro Model Astrocytoma U251 cells CVCL_0021
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 239.88 nM High B7-H3 expression (B7-H3 +++)
Method Description
Cancer cell lines U87, U251, U87/B7-H3 KO cells (3000 cells per well) at logarithmic growth stage were seeded in 96-well plates and allowed to adhere overnight at 37 °C in a humidified incubator of 5% CO2. After that, ADCs, 401 and MMAE were diluted at a certain concentration gradient and added to cell plates in triplicate, the cells were treated at 37 °C with 5% CO2 for 72 h. In addition, the complete medium without cells served as the blank and the cells cultured in medium alone served as vehicle control.

   Click to Show/Hide
In Vitro Model Glioblastoma U87 cells (B7-H3 KO) CVCL_0022
References
Ref 1 Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma